Protocol Ledger

NCT05171777 · Phase II · COMPLETED

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05171777 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-04 Enrollment: 179 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05171777
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)179 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05171777
Protocol FieldVerified Registry Value
NCT IdentifierNCT05171777
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment179 participants (ACTUAL)
Registered Start Date2022-04-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05171777
Hospital Research SiteLocationSite Profile
UPMC Hillman Cancer CenterPittsburgh, PAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI